Progress in the management of IPF-related acute exacerbations: a goal for patients, respirologists and intensivists
- PMID: 29467210
- DOI: 10.1183/13993003.00113-2018
Progress in the management of IPF-related acute exacerbations: a goal for patients, respirologists and intensivists
Conflict of interest statement
Conflict of interest: G. Raghu reports personal fees from Boehringer-Ingelheim, Sanofi and Veracyte; and other fees as a consultant for IPF studies from Boehringer-Ingelheim, BMS, Fibrogen, Gilead, Promedior, Roche-Genentech, Sanofi, United Therapeutics, UCB and Veracyte; all outside the submitted work.
Comment on
-
Idiopathic pulmonary fibrosis: lessons from clinical trials over the past 25 years.Eur Respir J. 2017 Oct 26;50(4):1701209. doi: 10.1183/13993003.01209-2017. Print 2017 Oct. Eur Respir J. 2017. PMID: 29074545 Review.
-
Progress in the management of IPF-related acute exacerbations: a goal for patients, respirologists and intensivists.Eur Respir J. 2018 Feb 21;51(2):1702419. doi: 10.1183/13993003.02419-2017. Print 2018 Feb. Eur Respir J. 2018. PMID: 29467208 No abstract available.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources